Allianz Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.3M Sell
34,339
-1,937
-5% -$903K 0.02% 705
2025
Q4
$16.4M Sell
36,276
-73,885
-67% -$31.8M 0.02% 684
2025
Q3
$43.1M Sell
110,161
-6,036
-5% -$2.52M 0.05% 374
2025
Q2
$51.7M Sell
116,197
-24,888
-18% -$11.5M 0.06% 312
2025
Q1
$68.4M Sell
141,085
-114,538
-45% -$53.4M 0.09% 215
2024
Q4
$103M Sell
255,623
-3,262
-1% -$1.51M 0.14% 150
2024
Q3
$120M Sell
258,885
-75,709
-23% -$36.4M 0.17% 125
2024
Q2
$157M Sell
334,594
-49,484
-13% -$21.5M 0.23% 94
2024
Q1
$161M Sell
384,078
-35,709
-9% -$15.1M 0.25% 88
2023
Q4
$171M Sell
419,787
-58,972
-12% -$21.8M 0.28% 72
2023
Q3
$166M Sell
478,759
-16,571
-3% -$5.8M 0.28% 63
2023
Q2
$174M Sell
495,330
-291,644
-37% -$98.3M 0.31% 55
2023
Q1
$248M Sell
786,974
-15,296
-2% -$4.59M 0.44% 40
2022
Q4
$232M Sell
802,270
-78,484
-9% -$23.9M 0.45% 45
2022
Q3
$255M Sell
880,754
-321,150
-27% -$92.4M 0.52% 33
2022
Q2
$339M Buy
1,201,904
+529,249
+79% +$142M 0.32% 67
2022
Q1
$176M Buy
672,655
+11,828
+2% +$2.81M 0.13% 168
2021
Q4
$145M Sell
660,827
-8,617
-1% -$1.68M 0.1% 228
2021
Q3
$121M Buy
669,444
+153,686
+30% +$30M 0.09% 231
2021
Q2
$104M Buy
515,758
+105,558
+26% +$22.1M 0.09% 224
2021
Q1
$88.1M Buy
410,200
+1,720
+0.4% +$378K 0.09% 239
2020
Q4
$96.5M Sell
408,480
-383,244
-48% -$87.9M 0.1% 209
2020
Q3
$215M Sell
791,724
-56,384
-7% -$15.6M 0.25% 85
2020
Q2
$246M Buy
848,108
+39,339
+5% +$10.7M 0.28% 71
2020
Q1
$192M Sell
808,769
-155,600
-16% -$35.7M 0.26% 89
2019
Q4
$211M Sell
964,369
-495,910
-34% -$100M 0.19% 110
2019
Q3
$247M Sell
1,460,279
-103,877
-7% -$18.4M 0.24% 80
2019
Q2
$287M Buy
1,564,156
+92
+0% +$16.1K 0.27% 69
2019
Q1
$288M Sell
1,564,064
-162,083
-9% -$29.9M 0.28% 66
2018
Q4
$286M Sell
1,726,147
-35,845
-2% -$6.21M 0.31% 61
2018
Q3
$340M Buy
1,761,992
+175,700
+11% +$31.3M 0.31% 60
2018
Q2
$270M Buy
1,586,292
+193,487
+14% +$30M 0.26% 67
2018
Q1
$227M Buy
1,392,805
+644,218
+86% +$105M 0.22% 91
2017
Q4
$112M Buy
748,587
+27,001
+4% +$4M 0.09% 274
2017
Q3
$110M Buy
721,586
+475,427
+193% +$71.6M 0.09% 251
2017
Q2
$31.4M Sell
246,159
-84,109
-25% -$10.1M 0.03% 743
2017
Q1
$35.9M Sell
330,268
-203,642
-38% -$17.9M 0.04% 666
2016
Q4
$39.3M Buy
533,910
+184,452
+53% +$15M 0.04% 678
2016
Q3
$30M Sell
349,458
-23,372
-6% -$2.21M 0.03% 741
2016
Q2
$32.1M Buy
372,830
+34,062
+10% +$2.94M 0.03% 639
2016
Q1
$26.9M Buy
338,768
+61,993
+22% +$5.61M 0.03% 638
2015
Q4
$34.9M Sell
276,775
-113,367
-29% -$13.7M 0.04% 519
2015
Q3
$40.6M Sell
390,142
-58,320
-13% -$7.49M 0.05% 460
2015
Q2
$55.4M Sell
448,462
-252,256
-36% -$31.8M 0.06% 397
2015
Q1
$82.7M Sell
700,718
-22,111
-3% -$2.65M 0.09% 226
2014
Q4
$85.9M Buy
722,829
+224,408
+45% +$25.3M 0.1% 245
2014
Q3
$56M Buy
498,421
+111,718
+29% +$10.6M 0.07% 337
2014
Q2
$36.6M Buy
386,703
+42,824
+12% +$3M 0.05% 407
2014
Q1
$24.3M Buy
343,879
+5,660
+2% +$448K 0.03% 499
2013
Q4
$25.1M Sell
338,219
-98,965
-23% -$6.89M 0.03% 487
2013
Q3
$33.1M Sell
437,184
-35,945
-8% -$2.86M 0.04% 418
2013
Q2
$37.9M Buy
+473,129
New +$34.8M 0.05% 371

Other funds holding VRTX

Allianz Asset Management's VRTX Position: Q1 2026 in Review

Allianz Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 5.3% in Q1 2026, selling an estimated $903K and leaving 34,339 shares worth $15.3M. The position accounts for 0.02% of the portfolio, ranked #705.

Allianz Asset Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $340M in Q3 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Allianz Asset Management held 34,339 shares of Vertex Pharmaceuticals worth $15.3M as of Q1 2026.
  • Allianz Asset Management sold 1,937 Vertex Pharmaceuticals shares in Q1 2026, an estimated $903K.
  • Vertex Pharmaceuticals made up 0.02% of Allianz Asset Management's portfolio in Q1 2026, its #705 holding.
  • Allianz Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Allianz Asset Management's Vertex Pharmaceuticals position peaked at $340M in Q3 2018.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.